IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). “Fiscal 2023 was characterized by remarkable growth and progress as we continue to advance our drug formulations through FDA trials,” said Ram Mukunda, CEO of IGC. “IGC-AD1 is delivering strong results as it progresses through phase 2B trials. We are delighted with the positive headway we are making in clinical trials, and we remain confident in the potential of IGC-AD1 to be a groundbreaking therapy, with the potential to treat Alzheimer’s and to manage devastating symptoms that separate families, increase admissions to nursing homes, and drive the cost of Alzheimer’s care. In addition to IGC-AD1, we continue to identify and acquire drug formulations that we believe have the potential to treat the symptoms brought on by a variety of chronic illnesses. Moreover, we continue to expand the market presence of our consumer products, as evidenced by a 129% increase in revenue compared to last year. Overall, we are very pleased with the progress we have made in Fiscal 2023 and believe that we are uniquely and advantageously positioned with a vertically integrated business model to continue driving growth through fiscal 2024 and beyond.”
To view the full press release, visit https://ibn.fm/EFMJj
About IGC Pharma Inc.
IGC Pharma develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps (“dysmenorrhea”), premenstrual syndrome (“PMS”), and chronic pain. IGC has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”) based formulation that is currently in a 146-person phase 2 clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). IGC Pharma also markets a wellness brand, Holief(TM), that targets women experiencing premenstrual syndrome and menstrual cramps.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.